Search for: "Fields v. Eli Lilly & Company" Results 21 - 40 of 56
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 Jan 2016, 7:28 am
**********PREVIOUSLY, ON NEVER TOO LATENever too late 78  [week ending on Sunday 27 December] – Zer-sum claim and lookalike products | 2015 Copyright Awards | Santa Claus and Section 52 | Jani writes on Dallas Buyers Club LLC v iiNet Limited | IP Hairballs |  Actavis v Eli Lilly | Power outage at USPTO | Santa's GC resigns | Pet rock and IP.Never too late 77 [week ending on Sunday 20… [read post]
26 May 2015, 7:42 am
  SJS/TEN is somewhat analogous in our sandbox to mesothelioma in asbestos cases, since plaintiffs often work backwards from the diagnosis to look for some drug company to sue. [read post]
26 Apr 2015, 6:14 pm
Complex technology requires complex patentability testsThis Kat is a practitioner in the field of biotech/pharma patents. [read post]
7 Dec 2014, 3:29 pm
Among the significant –- but, really, very-well indexed –- number of issues, the decision delves into novelty, inventive step, insufficiency by excessive claim breadth, added matter, and claim construction in light of the influential Actavis v Eli Lilly, another Arnoldian decision that the very same judge clarifies further in this ruling. [read post]
16 Dec 2013, 1:23 pm
Similarly in Actavis v Eli Lilly [2013] EWCA Civ 517, the Court of Appeal confirmed that the English courts have jurisdiction to hear claims for declarations of non-infringement in relation to foreign designations of European patents where there is no challenge to validity. [read post]
28 Apr 2013, 8:40 am
Reciting Seager v Copydex and Banks v EMI Songs, the former judge stated that 'where an inventor wanted to sell his idea for money, money is what he got'. [read post]
20 May 2012, 1:11 pm
 On the face of it, Plavix's patent expiry may have arguably paved the way for Eli Lilly & Co's and AstraZeneca's own blood-thinning drugs, Effient and Brilinta respectively, to gain more market share but the expiry of the patent does not mean that increasing the market share of their competitor drugs will be easy. [read post]
16 Apr 2012, 10:30 am by Nicholas R. Mattingly
Point - Counterpoint: The Debate Over Prior User RightsExactly who is to blame if a pharmaceutical company, say Eli Lilly, decides to invest billions of dollars and build a facility when they haven't adequately protected their own intellectual property? [read post]
5 Feb 2012, 5:01 pm by Lawrence Higgins
Eli Lilly's profit dropped 27% because of Zyprexa going generic. [read post]
2 Nov 2011, 12:57 pm
Still, you can’t blame the inventor for trying… The dispute in Human Genome Sciences v Eli Lilly is, by comparison, a whole other kettle of fish. [read post]
2 Nov 2011, 4:53 am
The Kat had this brilliant idea for what you get when you cross 'Neutrokine-a' with 'genome' Hot off the press and not yet digested, this morning's ruling of the United Kingdom's Supreme Court in Human Genome Sciences Inc. v Eli Lilly and Company [2011] UKSC 51, will be the subject of considerable analysis in the coming days and weeks. [read post]
24 Oct 2011, 2:52 am by Laura Sandwell
Human Genome Sciences Inc v Eli Lilly and Company, heard 18 July 2011. [read post]